✦ LIBER ✦

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat

✍ Scribed by Kamath, Ravi S.; Lukina, Elena; Watman, Nora; Dragosky, Marta; Pastores, Gregory M.; Arreguin, Elsa Avila; Rosenbaum, Hanna; Zimran, Ari; Aguzzi, Rasha; Puga, Ana Cristina; Norfleet, Andrea M.; Peterschmitt, M. Judith; Rosenthal, Daniel I.

Book ID: 125343311
Publisher: Springer
Year: 2014
Tongue: English
Weight: 554 KB
Volume: 43
Category: Article
ISSN: 0364-2348
DOI: 10.1007/s00256-014-1891-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improvements in skeletal manifestations

Improvements in skeletal manifestations in gaucher disease Type 1 patients receiving oral eliglustat during a phase 2 trial

✍ Ravi Kamath; Elena Lukina; Nora Watman; Marta Dragosky; Marcelo Iastrebner; Greg 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Eliglustat, an investigational oral ther

Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4years of treatment

✍ Lukina, Elena; Watman, Nora; Dragosky, Marta; Pastores, Gregory M.; Arreguin, El 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Eliglustat for Gaucher disease Type 1 (G

Eliglustat for Gaucher disease Type 1 (GD1): Safety results from a Phase 2 study after 2 years of treatment

✍ M. Judith Peterschmitt; Elena Lukina; Nora Watman; Marta Dragosky; Marcelo Iastr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Eliglustat, an investigational oral ther

Eliglustat, an investigational oral therapy for gaucher disease type 1 (GD1): Phase 2 results and assessment of patient responses and achievement of established therapeutic goals after 2 years of treatment

✍ Ana Cristina Puga; Elena Lukina; Nora Watman; Marta Dragosky; Marcelo Lastrebner 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Eliglustat, an investigational oral ther

Eliglustat, an investigational oral therapy for Gaucher disease type 1 (GD1): Phase 2 results and assessment of patient responses and achievement of established therapeutic goals after 2 years of treatment

✍ Marta Dragosky; Elena Lukina; Nora Watman; Gregory Pastores; Marcelo Iastrebner; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 70 KB

EDGE: A Phase 3 study evaluating once ve

EDGE: A Phase 3 study evaluating once versus twice daily dosing of eliglustat in patients with Gaucher disease type 1: interim results from the lead-in-period

✍ Charrow, Joel; Ida, Hiroyuki; Hollak, Carla; Amato, Dominick; Cravo, Renata; Kaw 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB